Zencore Biologics is a CDMO provider headquartered in Shanghai, China. Zencore has an R&D facility located in Maryland, United States. Zencore provides one-stop-shop services for biologics from pre-clinical research to commercial manufacturing and customized cell culture medium services for mammalian cell-based protein production. Zencore supports the R&D and production of protein drugs for our domestic and global clients. The services and solutions provided include:
• Biologics CDMO
• Antibody drug conjugate (ADC) CDMO
• Cell culture medium support: the development & manufacturing
• Analytical development and characterization services
• QC testing & regulatory filings
With two CDMO facilities of 600,000 sq ft in total, Zencore provides a pilot scale production with 4×200L and 1×500L single use bioreactors, and the state-of-the-art commercial GMP manufacturing services with 3×2,000L single use and 3×5,000L stainless steel bioreactors in separate production suites, followed by corresponding purification, formulation, and fill and finish lines.
21st century is the epoch for biotechnology and biopharmaceutical industry. Rapid advancement in life sciences, technologies, and healthcare has brought numerous previously untreatable diseases under control with significant improvement on patient survival rate and quality of life. These changes, in turn, have presented many opportunities and challenges for the CROs and CDMOs to support the R&D of biopharmaceutical industries. With the aspiration to contribute to a healthier world, Zencore Biologics was incepted.
A purposeful enterprise requires a group of professionals with ambition, vision and passion. Zencore is privileged to work with many experienced entrepreneurs, talented scientists, and skilled engineers who share the common aspirations and values for our course.
Since its establishment in 2017, Zencore continuously innovates in technologies and bioprocesses and improve operation efficiencies. We have been at the forefront of supporting the growth of biopharmaceutical R&D and have earned a good reputation among our global clients.
With the strong belief on "Of the people, by the people, for the people", we will unleash huge potentials and creativities. Adhering to our principles of "Pursue the Truth, Commit the Utmost, Strive for Excellence" and alongside our clients, we will create a better and healthier world.
Jianxin Chen ,CEO of Zencore Biologics Co., Ltd.
Since its establishment in 2017, Zencore Biologics has become the industry leader in large-scale mammalian cell culture technology. Our team has achieved the record high expression level in the fed-batch culture process for antibody production, which currently stands at 15 g/L.
Learn More...
